Skip to main content
. Author manuscript; available in PMC: 2015 Mar 9.
Published in final edited form as: Biol Blood Marrow Transplant. 2010 Jan 29;16(4):555–559. doi: 10.1016/j.bbmt.2009.12.004

Table 1.

Patient Characteristics

Number of patients 14
Age (median, range) 59 (50-67)
Sex
    Male 9
Diagnosis
    PMF 11
    SMF 4
Lille Score at diagnosis of the time of LT
    0 4
    1 7
    2 3
Median time from MF to LT (months) (range) 38 (10-144) (n = 13)
Number of patients with prior splenectomy 5
Prior therapy for myelofibrosis
    Hydroxyurea 9
    Thalidomide/lenalidomide 4
    Interferon 3
    Azacitidine/decitabine 2
    Anabolic steroids 2
    Erythropoietin 1
    Bortezomib 1
Number of patients who received cytoreductive chemotherapy prior to transplant 13
Number of patients with LT in CR at transplant 6
Cytogenetics at LT
    Normal 3
    CRS 1 abnormalities (+1, 1q-, t(1;6), der (1;19), t(1;17), dup(1), del(1)) 7
    CRS 7 abnormalities (del 7, 7q-, t(7;10)) 3
    CRS 8 abnormalities (+8, −8, t(3;8)) 4
    Complex karyotype 4

PMF indicates primary myelofibrosis; SMF, secondary myelofibrosis; LT, leukemic transformation; CR, complete remission from acute myelogenous leukemia; CRS, chromosome; MF, myelofibrosis.